Ucb SA

Chart & Performance

D1W1MN

P/E

12.89

P/S

2.23

EPS

5.60

Div Yield, %

0.98%

Shrs. gr., 5y

0.82%

Rev. gr., 5y

4.60%

Revenues

6.15b

+17.14%

Net income

1.07b

+210.50%

CFO

1.24b

+63.21%

Dividend

Apr 26, 20240.77726 USD/sh

Earnings

Apr 25, 2025

Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

URL

https://www.ucb.com

IPO date

Jan 02, 1987

Employees

8,600

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	6,152,000 17.14%	5,252,000 -4.80%	5,517,000 -4.50%
Cost of revenue	5,880,000	5,161,000	5,247,000
Unusual Expense (Income)
NOPBT	272,000	91,000	270,000
NOPBT Margin	4.42%	1.73%	4.89%
Operating Taxes	98,000	98,000	91,000
Tax Rate	36.03%	107.69%	33.70%
NOPAT	174,000	(7,000)	179,000
Net income	1,065,000 210.50%	343,000 -17.94%	418,000 -60.49%
Dividends	(259,000)	(252,000)	(247,000)
Dividend yield	0.69%	1.64%	1.72%
Proceeds from repurchase of equity	(162,000)	(40,000)	(405,000)
BB yield	0.43%	0.26%	2.83%
Debt
Debt current	63,000	85,000	262,000
Long-term debt	3,169,000	3,157,000	2,638,000
Deferred revenue			100,000
Other long-term liabilities	735,000	666,000	677,000
Net debt	1,511,000	2,150,000	1,653,000
Cash flow
Cash from operating activities	1,242,000	761,000	1,045,000
CAPEX	(234,000)	(238,000)	(371,000)
Cash from investing activities	282,000	(440,000)	(1,580,000)
Cash from financing activities	(818,000)	(308,000)	144,000
FCF	72,000	(225,000)	20,000
Balance
Cash	1,757,000	923,000	1,069,000
Long term investments	(36,000)	169,000	178,000
Excess cash	1,413,400	829,400	971,150
Stockholders' equity	7,979,000	7,298,000	7,397,000
Invested Capital	12,376,600	11,892,600	11,619,850
ROIC	1.43%		1.66%
ROCE	1.96%	0.70%	2.08%
EV
Common stock shares outstanding	195,007	195,190	194,834
Price	192.20 143.60%	78.90 7.26%	73.56 -26.70%
Market cap	37,480,428 143.37%	15,400,491 7.46%	14,331,989 -26.45%
EV	38,991,428	17,550,491	15,984,989
EBITDA	913,000	782,000	855,000
EV/EBITDA	42.71	22.44	18.70
Interest	159,000	144,000	71,000
Interest/NOPBT	58.46%	158.24%	26.30%